{"id":"arv-110-in-combination-with-abiraterone","brandName":"ARV-110 in Combination with Abiraterone","genericName":"ARV-110 in Combination with Abiraterone","companyId":"arvinas-androgen-receptor-inc","companyName":"Arvinas Androgen Receptor, Inc.","phase":"phase_1","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"ARV-110, a PROTAC degrader of the androgen receptor, is being evaluated in combination with abiraterone for metastatic castration-resistant prostate cancer (mCRPC). The Phase 1 trial has been completed with promising safety and efficacy data, positioning it as a potential best-in-class therapy.","enrichmentLevel":3,"visitCount":1,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARV-110 is a selective androgen receptor degrader (SARD) that targets the androgen receptor, a protein that plays a key role in the growth and spread of prostate cancer cells.","oneSentence":"Androgen receptor inhibitor","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"30%","effect":"Fatigue"},{"rate":"20%","effect":"Hypertension"},{"rate":"15%","effect":"Diarrhea"}]},"trials":[],"indications":{"approved":[{"name":"Prostate cancer"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}